Area of research
Oncology · Organic Chemistry
Research interest
Research focused on Immune checkpoint and Cancer research, with related work in Trimethoprim, Immune reconstitution inflammatory syndrome, Blockade. Notable publications include 'Immune Modulating Antibody–Drug Conjugate (IM-ADC) for Cancer Immunotherapy', 'No Statistically Apparent Difference in Antifungal Effectiveness Observed Among Trimethoprim/Sulfamethoxazole Plus Clindamycin or Caspofungin, and Trimethoprim/Sulfamethoxazole...', and 'Initiating antiretroviral therapy within 2 weeks of anti-Pneumocystis treatment does not increase mortality or AIDS-defining events in patients with HIV-associated moderate to...'.
No Statistically Apparent Difference in Antifungal Effectiveness Observed Among Trimethoprim/Sulfamethoxazole Plus Clindamycin or Caspofungin, and Trimethoprim/Sulfamethoxazole Monotherapy in HIV-Infected Patients with Moderate to Severe Pneumocystis Pneumonia: Results of an Observational Multicenter Cohort Study
Initiating antiretroviral therapy within 2 weeks of anti-Pneumocystis treatment does not increase mortality or AIDS-defining events in patients with HIV-associated moderate to severe Pneumocystis pneumonia: results of a prospective observational multicenter study
Immune Modulating Antibody–Drug Conjugate (IM-ADC) for Cancer Immunotherapy